Sandoz Hones Biosimilars Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis generics unit pursues two different approaches for the human growth hormone Omnitrope and the epoetin alfa follow-on Binocrit.
You may also be interested in...
Biosimilars Create Class-wide Competition, German Experience Finds
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
Biosimilars Create Class-wide Competition, German Experience Finds
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
Europe’s Biosimilars Ahead Of U.S., But Still Early
Beware confusion with generics, Biosimilars 2000 speakers warn.